B2B ad examples

Hipp Health team is heading to Atlantic City for Autism New Jersey’s 44th annual conference on October 22-23. I’ll be there with Dawn Robinson and Shomarr Malone, and I’m looking forward to connecting with fellow ABA professionals. I love hearing what other teams are trying and what they’re learning along the way. If you’ve made a change that’s helped your clinicians or made life easier for families, come tell us about it. Those everyday wins are worth sharing. You can schedule time with us at the conference here: https://lnkd.in/eB7_sY57

Nous recrutons des médecins (H/F) dans nos cliniques SMR, de santé mentale et maisons de retraite. Rejoindre emeis, c’est contribuer à un projet médical fort, où qualité du soin, interdisciplinarité et amélioration continue guident chaque geste.

What does a healthy practice look like? We asked 1,000+ clinicians. Take the free 5-minute assessment and see where yours stands.

The first non-gel spacer for prostate cancer radiation therapies, the BioProtect Balloon Spacer creates symmetrical space with whole-gland coverage, including at the prostate apex. Discover the BioProtect difference.

Following her in-depth sharing at the IQVIA workshop at DIA China 2026, Leanne Magné , Senior Vice President & Head R&D Solutions, Asia-Pacific and Japan, shares key perspectives on navigating today’s clinical development landscape and the considerations shaping trial delivery. If you missed the session, explore the full 3-part video series and catch the key insights.

Dedicated Phase I oncology centres are changing how sponsors approach trial timelines, site selection and execution. In this 3-part video series, Dr Shiraj Sen, Director of Clinical Research at NEXT Oncology, shares his perspective on specialised Phase I oncology centres, consistent execution across site networks, and stronger site-CRO-sponsor collaboration. Explore the full 3-part video series.

Join Foundation Medicine at #ESMO26! Our team looks forward to engaging with the international oncology community on the latest research advancing precision medicine and oncology care and hosting expert-led discussions at our booth. Learn more about our high-quality tests and services, including our new molecular residual disease (MRD) offering, which was recently named a winner in The Scientist’s 2026 Top Innovations contest.

Join Foundation Medicine for our Booth Talks series at #ESMO26. Connect with our experts during these rapid-fire, high-impact sessions to learn more about the latest innovations happening in precision medicine and diagnostics.

“A couple of thousand.” That was Stefan Heitmeier's answer when I asked how many molecules his team tested with one question in mind: How do you find a medicine that could prevent secondary strokes? Kudos to the team for their relentless work in service of stroke patients. Watch the whole video on YouTube: https://lnkd.in/eCE8rd5z

Come see us at ANESTHESIOLOGY 2026, Oct. 17-19! Visit us at Booth 1635.

Varje kundmöte spelar roll och din kompetens gör skillnad för människors hälsa, varje dag. Här får du ett uppdrag som är viktigt på riktigt. Vi finns från norr till söder - vi finns där du är.

Most automation sorts mail into folders and hands it back to you. Cofactor's agents read the letter, understand what the payer wants, and act on it the way a trained specialist would.

Cofactor deploys AI agents that take on the administrative work slowing health systems down so your team can focus on care instead of paperwork.

Multiple validated - structurally distinct hits against a novel target - in under three months. BioAge Labs (Nasdaq: BIOA) put our screening to the test.

Was kann ein OP-Team erreichen, wenn Planbarkeit die Grundlage des Tagesablaufs bildet? Das Intuitive Ökosystem unterstützt Teams dabei, standardisierte Prozesse zu etablieren – als Grundlage für effiziente, leistungsstarke da Vinci Programme mit hohem Operationsvolumen. Operateurinnen und Operateure erhalten mehr Kontrolle bei der Planung ihrer Abläufe, Operationszeiten und Ergebnisse. Die Auswirkungen reichen dabei oft weit über die Konsole hinaus und können einen gemeinsamen Rhythmus im gesamten OP-Team schaffen. Wenn jedes Teammitglied weiß, was es erwarten kann, ist die Zusammenarbeit besser abgestimmt – für mehr Agilität und eine gute Vorbereitung. Diese Beständigkeit kann zu einem reibungslosen OP-Ablauf beitragen, Teams dabei unterstützen, mehrere Eingriffe pro Tag zuverlässig zu koordinieren und gleichzeitig eine präzisere sowie besser vorhersehbare Patientenversorgung zu ermöglichen. Den Weg zu mehr Vorhersehbarkeit ebnen. Das ist Intuitive.

„Sie erhalten nicht nur die Technologie, sondern auch Zugang zum umfassenden Intuitive Ökosystem.“ Der Aufbau eines effizienten minimalinvasiven Programms erfordert mehr als nur die Technologie. Das vollständig integrierte Intuitive Ökosystem ergänzt das da Vinci Operationssystem durch umfassende Unterstützung und schafft Mehrwert durch professionelle Aus- und Weiterbildungsangebote sowie Lösungen zur Programmoptimierung. Dieser vernetzte Ansatz unterstützt Krankenhäuser dabei, ihre Ziele zu erreichen. Er gibt den Teams das Vertrauen, das sie benötigen, um sich auf das Wesentliche zu konzentrieren: die bestmögliche Versorgung ihrer Patientinnen und Patienten. Technologie, gestärkt durch ein umfassendes Ökosystem aus Services und Expertise. Das ist Intuitive.

Parabilis Medicines started with individual AI agents. Now they’re taking the next step with Science Foundries. We’ve been working with Parabilis to deploy teams of agents across entire scientific processes, from protein production to screening and lead optimization. The goal? Less waiting between experiments and more time for scientists to focus on the decisions that move programs forward. Read about it: https://lnkd.in/eGyX4_sz

Working on herbicide tolerance crop traits? Is your expression host delivering active, correctly folded, purified protein for downstream studies? 🌱 In Part 2 of our crop trait series, we examine major herbicide-tolerance (HT) enzyme, including EPSPS, HPPD, ALS/AHAS, PAT, AAD, and DMO, and address the gap between trait discovery and scalable protein supply. 👉 Read the full blog article here: https://lnkd.in/gHHMg83d/?utm_campaign=CropBlog2&utm_source=linkedin&utm_medium=paid&utm_id=1233493356&hsa_acc=512604048&hsa_cam=1233493356&hsa_grp=914658386&hsa_ad=1649195406&hsa_net=linkedin&hsa_ver=3

Even highly automated labs can get slowed down by manual handoffs between experiments. Benchling's Head of AI Nicholas Larus-Stone spoke with R&D World about how AI agents helped one biologics lab overcome this bottleneck and increase throughput. Plus, how our newly launched Science Foundries bring agents together to coordinate work across entire scientific processes. Read the full interview: https://lnkd.in/eC_Vj4Cy

Get insights from 100 payer leaders on technology, analytics, AI, and value-based care.

Working on herbicide tolerance crop traits? Is your expression host delivering active, correctly folded, purified protein for downstream studies? 🌱 In Part 2 of our crop trait series, we examine major herbicide-tolerance (HT) enzyme, including EPSPS, HPPD, ALS/AHAS, PAT, AAD, and DMO, and address the gap between trait discovery and scalable protein supply. 👉 Read the full blog article here: https://lnkd.in/gHHMg83d/?utm_campaign=CropBlog2&utm_source=linkedin&utm_medium=paid&utm_id=1233493356&hsa_acc=512604048&hsa_cam=1233493356&hsa_grp=914816266&hsa_ad=1649299886&hsa_net=linkedin&hsa_ver=3

Generate functional, quantitative assay data in just three easy steps. Thaw. Plate. Run! Explore how ready-to-use, no-wash eXpress™ cell-based assay kits help drug discovery teams to move quickly from target identification to lead optimization. Eurofins DiscoverX eXpress Assay Kits: - Screen targets & identify promising activity - Confirm functional responses & mechanism of action (MOA) - Rank compounds & prioritize the next stage of discovery 🎥 WATCH the latest video & learn how researchers are simplifying early drug discovery with a homogeneous assay workflow that delivers sensitive & reproducible functional data.

Remember the first time you saw data that made you feel, “This could actually change everything”? That’s the moment you get when 30.6% of 80 billion compounds hit, and binding poses land within 1.2Å before a crystal structure even exists. You’re not just screening; you’re watching your odds of finding the right molecule transform from a grind into a genuine shot at the breakthrough you’ve been chasing—faster than AlphaFold3, Boltz-1, or Chai-1 on novel targets.

Rejoignez Filieris !